CryoPort (NASDAQ:CYRX) issued its quarterly earnings results on Thursday. The consumer goods maker reported ($0.08) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.08), Briefing.com reports. The company had revenue of $8.46 million during the quarter, compared to the consensus estimate of $7.94 million. CryoPort had a negative return on equity of 26.25% and a negative net margin of 35.71%. CryoPort’s revenue was up 82.7% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.09) EPS.
Shares of NASDAQ CYRX traded up $3.01 during trading on Friday, hitting $23.19. 1,456,924 shares of the company traded hands, compared to its average volume of 329,115. CryoPort has a 1 year low of $8.28 and a 1 year high of $23.69. The stock has a 50-day moving average of $19.38. The company has a market cap of $626.88 million, a price-to-earnings ratio of -74.81 and a beta of 0.82. The company has a debt-to-equity ratio of 0.42, a current ratio of 11.57 and a quick ratio of 11.52.
Hedge funds and other institutional investors have recently made changes to their positions in the company. BNP Paribas Arbitrage SA purchased a new stake in shares of CryoPort during the 1st quarter valued at $74,000. Metropolitan Life Insurance Co. NY grew its stake in shares of CryoPort by 356.6% during the 4th quarter. Metropolitan Life Insurance Co. NY now owns 8,607 shares of the consumer goods maker’s stock valued at $95,000 after buying an additional 6,722 shares during the period. MML Investors Services LLC purchased a new stake in shares of CryoPort during the 4th quarter valued at $157,000. Bank of America Corp DE grew its stake in shares of CryoPort by 92.3% during the 4th quarter. Bank of America Corp DE now owns 16,037 shares of the consumer goods maker’s stock valued at $176,000 after buying an additional 7,697 shares during the period. Finally, Handelsinvest Investeringsforvaltning purchased a new stake in CryoPort during the 2nd quarter worth $183,000. 53.92% of the stock is owned by institutional investors.
CryoPort Company Profile
CryoPort, Inc engages in the provision of logistics solutions to the life science industry. It also provides logistics solutions for biologic materials such as immunotherapies, stem cells, CAR-T cells, and reproductive cells for clients worldwide, including points-of-care, clinical research organizations central laboratories, biopharmaceuticals, contract manufacturing, health centers, and university researchers.
Recommended Story: Preferred Stock
Receive News & Ratings for CryoPort Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoPort and related companies with MarketBeat.com's FREE daily email newsletter.